Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial

Pharmacogenomics Journal

Volumn 15, Issue 1, 2015, Pages 63-68

  Le Morvan, V ^a   Litiere S ^b   Laroche Clary, A ^a   Ait Ouferoukh, S ^a   Bellott, R ^a   Messina, C ^b   Cameron, D ^c   Bonnefoi, H ^a   Robert, J ^a  

^a INSERM   (France)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL DEHYDROGENASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1B1; DNA; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FORMALDEHYDE; PARAFFIN; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; ANTINEOPLASTIC AGENT;

ADH1C GENE; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYP1B1 GENE; DNA DAMAGE; DNA EXTRACTION; EMBEDDING; GENE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MDM2 GENE; MDM4 GENE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TP53BP1 GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; CLINICAL TRIAL; FEMALE; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84921865116     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.24     Document Type: Article

References (24)

1. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet 2013; 14: 23-34.
2. Wheeler HE, Dolan ME. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics 2012; 13: 55-70.
3. Le Morvan V, Bellott R, Moisan F, Mathoulin-Pélissier S, Bonnet J, Robert J. Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel. Pharmacogenomics 2006; 7: 843-852.
4. Faur N, Araud L, Laroche-Clary A, Kanno J, Toutain J, Yamori T et al. The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models. Br J Cancer 2009; 101: 350-356.
5. Laroche-Clary A, Le Morvan V, Yamori T, Robert J. Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models. Mol Cancer Ther 2010; 9: 3315-3321.
6. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007; 26: 1317-1323.
7. Beuten J, Gelfond JA, Byrne JJ, Balic I, Crandall AC, Johnson-Pais TL et al. CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. Carcinogenesis 2008; 29: 1751-1757.
8. Chen B, Qiu LX, Li Y, Xu W, Wang XL, Zhao WH et al. The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501 subjects. Lung Cancer 2010; 70: 247-252.
9. Salinas-Sánchez AS, Donate-Moreno MJ, López-Garrido MP, Giménez-Bachs JM, Escribano J. Role of CYP1B1 gene polymorphisms in bladder cancer susceptibility. J Urol 2012; 187: 700-706.
10. Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011; 12: 527-539.
11. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995; 92: 3963-3967.
12. Robert J, Aitouferoukh S, Laurand-Quancard A, Laroche-Clary A, Hubert C, Le Morvan V. Identification of novel single-nucleotide polymorphisms associated with anticancer drug effects using the SNPChip384 platform. Proc Am Assoc Cancer Res 2012, Abstract #1872.
13. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65-70.
14. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat 2001; 29: 1165-1188.
15. Bonnefoi H, Litière S, Piccart M, Macgrogan G, Fumoleau P, Brain E et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann Oncol 2014; 25: 1128-1136.
16. Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 2007; 16: 2717-2723.
17. Atwal GS, Kirchhoff T, Bond EE, Montagna M, Menin C, Bertorelle R et al. Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci USA 2009; 106: 10236-10241.
18. Wu IC, Zhao Y, Zhai R, Liu CY, Chen F, Ter-Minassian M et al. Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk. Carcinogenesis 2011; 32: 502-506.
19. Schults MA, Chiu RK, Nagle PW, Wilms LC, Kleinjans JC, van Schooten FJ et al. Genetic polymorphisms in catalase and CYP1B1 determine DNA adduct formation by benzo(a)pyrene ex vivo. Mutagenesis 2013; 28: 181-185.
20. Le Morvan V, Auzanneau C, Pasquies A, Brault M, Robert J, Lansiaux A. Relationship between cytochrome P450 1B1 (CYP1B1) and head-and-neck cancer cells proliferation, dissemination and chemosensitivity to anticancer drugs. Proc Am Assoc Cancer Res 2013, Abstract #2200.
21. Wade M, Li YC, MDM2 Wahl GM. MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13: 83-96.
22. Höög JO, Hedén LO, Larsson K, Jö rnvall H, von Bahr-Lindström H. The gamma 1 and gamma 2 subunits of human liver alcohol dehydrogenase. cDNA structures, two amino acid replacements, and compatibility with changes in the enzymatic properties. Eur J Biochem 1986; 159: 215-218.
23. Coutelle C, Höhn B, Benesova M, Oneta CM, Quattrochi P, Roth HJ et al. Risk factors in alcohol associated breast cancer: alcohol dehydrogenase polymorphism and estrogens. Int J Oncol 2004; 25: 1127-1132.
24. Wang L, Zhang Y, Ding D, He X, Zhu Z. Lack of association of ADH1C genotype with breast cancer susceptibility in Caucasian population: a pooled analysis of case-control studies. Breast 2012; 21: 435-439.